Related Content
Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. (Pghoto by Dave Fornell)
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES.
The Fortitude sirolimus-eluting bioresorbable stent.
Fantom image courtesy of REVA Medical Inc.
Image courtesy of Reva Medical Inc.
Image courtesy of Reva
Abbott has spearheaded bioresorbable stent technology with the development with its BVS. By far the BVS has the most clinical experience, with more than 13,000 patients around the world having been treated with the device.
